



MSD has agreed to acquire cancer-focused biopharmaceutical company Terns Pharmaceuticals in a deal valued at $6.7 billion, marking the latest in a series of multibillion-dollar acquisitions as the...
From tradingview.comMerck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.
From business-news-today.com
Merck (NYSE: MRK) announced Tuesday it has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for $53.00 per share in cash —...
From channelchek.comMerck is acquiring Terns Pharmaceuticals for $6.7 billion cash, driven by the potential of TERN-701. Shareholder rights firms are investigating the deal over potential breaches. This acquisition...
From kavout.com